Baricent - 2mg

Tablet

Pack Size : 10 Tablet x 1 Strip

Generics : Baricitinib

Manufacturer : Incepta Pharmaceuticals Ltd.

Best Price * TK 250.00

* Delivery will be done in Dhaka city only.

Alternative Product

Tablet Baritor - 2mg Square Pharmaceuticals Ltd.

Tk 25.00

Tablet BARICIT - 2 MG Delta Pharma Ltd

Tk 20.00

More Information About - Baricent - 2mg

Description

Generic Name

Baricitinib

Precaution

Serious and sometimes fatal infections may develop owing to bacterial, mycobacterial, invasive fungal, viral, or other opportunistic pathogens reported; may cause reactivation of latent TB or viral infections Consider risks and benefits before initiating in patients with chronic or recurrent infection, history of serious or opportunistic infection, underlying conditions predisposing them to infection, or patients who have been exposed to tuberculosis or have resided or traveled in areas of endemic tuberculosis or mycoses Consider TB therapy for patients with a negative test for latent TB but who have risk factors for TB infection; consultation with a physician with expertise in TB recommended to aid in decision about whether initiating anti-TB therapy is appropriate If a new infection develops during treatment, promptly initiate diagnostic tests appropriate for an immunocompromised patient; if necessary, initiate appropriate antimicrobial therapy and closely monitor; interrupt baricitinib therapy if patient unresponsive to treatment If herpes zoster occurs, interrupt treatment until episode resolves Malignancies were observed in clinical studies; non-melanoma skin cancers (NMSCs) reported; periodic skin examination is recommended for patients who are at increased risk for skin cancer Perform screening for viral hepatitis in accordance with clinical guidelines before starting therapy; unknown impact on chronic viral hepatitis reactivation Increased incidence of thrombosis, including DVT and PE, observed compared with placebo; caution in patients at increased risk of thrombosis Gastrointestinal perforation reported in clinical studies, although the role of JAK inhibition in these events is unknown May increase incidence of neutropenia, lymphopenia, anemia, or elevated LFTs or lipids; monitor laboratory values at baseline and periodically during treatment

Indication

Rheumatoid Arthritis

Contra Indication

N/A

Dose

Side Effect

>10% Upper respiratory tract infections (16.3%) 1-10% Nausea (2.7%) Increased LFTs (1-2%) Platelet elevations (1-2%) Herpes zoster infection (1%) <1% Acne (<1%) Herpes simplex infection (0.8%) Neutropenia (0.3%)

Pregnancy Category

Name : Not Classified

Description

FDA has not yet classified the drug into a specified pregnancy category.

Mode of Action

Janus kinases (JAKs) pathways inhibitor; JAK consists of a group of intracellular tyrosine kinases that transmit signals from cytokine or growth factor-receptor interactions on the cellular membrane to influence cellular processes of hematopoieses and immune cell function Within the signaling pathway, JAKs phosphorylate and activate signal transducers and activators of transcription (STATs), which modulate intracellular activity including gene expression; baricitinib modulates the signaling pathway at the point of JAKs, preventing the phosphorylation and activation of STATs

Interaction

Avoid use of live vaccines; update immunizations in agreement with current immunization guidelines before initiating Coadministration with strong OAT3 inhibitors may increase baricitinib systemic exposure

Pregnancy Category Note

Pregnancy Data in pregnant women are insufficient to inform a drug-associated risk for major birth defects or miscarriage Animal studies In animal embryo-fetal development studies, oral baricitinib administration to pregnant rats and rabbits at exposures equal to and greater than ~20 and 84 times the maximum recommended human dose (MRHD), respectively, resulted in reduced fetal body weights, increased embryo lethality (rabbits only), and dose-related increases in skeletal malformations Lactation Unknown if distributed in human breast milk Baricitinib is present in the milk of lactating rats Owing to species-specific differences in lactation physiology, the clinical relevance of these data are not clear Because of the potential for serious adverse reactions in nursing infants, advise women not to breastfeed while taking baricitinib

Adult Dose

Rheumatoid Arthritis Indicated for adults with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response to one or more tumor necrosis factor (TNF) antagonist therapies May be used as monotherapy or in combination with methotrexate or other nonbiologic disease-modifying antirheumatic drugs (DMARDs) 2 mg PO qDay COVID-19 (EUA) Emergency use authorization (EUA) issued by the FDA for use, in combination with Remdesivir, for treatment of suspected or laboratory confirmed coronavirus disease 2019 (COVID-19) in hospitalized patients aged >2 years who require supplemental oxygen, invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO) Adults: 4 mg PO qDay Recommended treatment duration is 14 days or until hospital discharge, whichever comes first; optimal treatment duration unknown Hepatic impairment Rheumatoid arthritis Mild or moderate: No dose adjustment required Severe: Not recommended COVID-19 Increased ALT/AST: Consider interruption until the diagnosis of drug-induced liver injury is excluded Severe: Not studied; use only if benefits outweigh the risks

Child Dose

COVID-19 (EUA) Emergency use authorization (EUA) issued by the FDA for use, in combination with Remdesivir, for treatment of suspected or laboratory confirmed coronavirus disease 2019 (COVID-19) in hospitalized patients aged >2 years who require supplemental oxygen, invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO) 2 to <9 years: 2 mg PO qDay >9 years: 4 mg PO qDay Recommended treatment duration is 14 days or until hospital discharge, whichever comes first; optimal treatment duration unknown

Renal Dose

Renal impairment Rheumatoid arthritis Moderate (eGFR 30-60 mL/min/1.73 m2): Decrease to 1 mg/day Severe (eGFR <30 mL/min/1.73 m2): Not recommended (not studied) COVID-19 eGFR ?60 mL/min/1.73 m2: No dose adjustment eGFR 30 to <60 mL/min/1.73 m2: Decrease to 2 mg/day eGFR 15 to <30 mL/min/1.73 m2: Decrease to 1 mg/day eGFR <15 mL/min/1.73 m2, patients on dialysis, have end-stage renal disease, or have acute kidney injury: Not recommended

Administration

May take with or without food

Disclaimer

The information provided herein are for informational purposes only and not intended to be a substitute for professional medical advice, diagnosis, or treatment. Please note that this information should not be treated as a replacement for physical medical consultation or advice. Great effort has been placed to provide accurate and comprehensive data. However, Medicart along with its authors and editors make no representations or warranties and specifically disclaim all liability for any medical information provided on the site. The absence of any information and/or warning to any drug shall not be considered and assumed as an implied assurance of the Company.